Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice

Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice

Abstract The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical administration of live Mycobacterium bovis BCG. Previous studies suggest improving this therapy by implementing non-pathogenic mycobacteria, such as Mycobacterium brumae, and/or different vehicl...

Full description

Bibliographic Details
Main Authors: Estela Noguera-Ortega, Rosa M. Rabanal, Elisabet Gómez-Mora, Cecilia Cabrera, Marina Luquin, Esther Julián
Format: Article
Language:English
Published: Nature Publishing Group 2018-10-01
Series:Scientific Reports
Subjects:
Brumath
Mycobacteria Treatment
Splenocyte Proliferation
Systemic Immune Response
Regulated On Activation, Normal T Cell Expressed And Secreted (RANTES)
Online Access:https://doi.org/10.1038/s41598-018-33253-w

Internet

https://doi.org/10.1038/s41598-018-33253-w

Similar Items